FDA approves Biogen’s Alzheimer's drug, Aduhelm

By Rachel Arthur

The US Food and Drug Administration (FDA) has approved Biogen’s Aduhelm (aducanumab) for the treatment of Alzheimer’s: making it the first new treatment approved for the disease since 2003.

(Image: Getty/HS3RUS)


How invested is pharma in sustainability?

By Ben Hargreaves

As a day of climate strikes unfolds across the world, we ask how far pharma is engaged on the issue, as well as noting recent innovations that suggest companies are looking at what can be done.

Biogen digs into Europe

Biogen digs into Europe

Biotechnology company Biogen this week celebrated its 25th
anniversary by breaking the ground on a large-scale manufacturing
facility in Hillerød, Denmark, marking the company's first
development phase for the region and a greater...


Follow us


View more


Featured Suppliers

All suppliers